Amgen DLL-3/CD3 Plus PD-L1 Posts 21.1-Month OS in First-Line Small Cell Lung Cancer, Setting New Record

Amgen's DLL-3/CD3 plus PD-L1 regimen showed an overall survival of 21.1 months in first-line small cell lung cancer, which the source describes as a record for OS in this indication. The news is set on day two of the 2026 ESMO Congress in Madrid, Spain; full trial design and additional endpoint data were not listed.